Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRX Adhera Therapeutics	$0.01	$0.00	$0.00 ▼ $0.01	$116K	4	100 shs	N/A
GLGLF GLG Life Tech		$0.01	$0.01 ▼ $1.12	$430K	1.91	N/A	N/A
ORGS Orgenesis	$1.00 +4,445.5%	$0.89	$0.00 ▼ $7.50	$4.80M	0.44	7,109 shs	267 shs
WINT Windtree Therapeutics	$0.10 +1.5%	$0.63	$0.09 ▼ $534.00	$384K	0.63	5.83 million shs	991,486 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRX Adhera Therapeutics	0.00%	0.00%	+9,900.00%	+9,900.00%	+25.00%
GLGLF GLG Life Tech	0.00%	0.00%	0.00%	0.00%	0.00%
ORGS Orgenesis	-78.00%	-31.25%	-97.80%	-98.90%	+2,199,900.00%
WINT Windtree Therapeutics	-14.42%	-78.60%	-89.46%	-87.70%	-99.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRX Adhera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLGLF GLG Life Tech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	1.6057 of 5 stars	0.0	3.0	0.0	4.4	1.7	0.0	0.0
WINT Windtree Therapeutics	2.5149 of 5 stars	3.0	4.0	0.0	0.0	2.7	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRX Adhera Therapeutics	0.00	N/A	N/A	N/A
GLGLF GLG Life Tech	0.00	N/A	N/A	N/A
ORGS Orgenesis	0.00	N/A	N/A	N/A
WINT Windtree Therapeutics	2.00	Hold	$350.00	333,551.10% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRX Adhera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
GLGLF GLG Life Tech	$10.62M	0.00	N/A	N/A	($2.00) per share	0.00
ORGS Orgenesis	$662K	7.25	N/A	N/A	($6.58) per share	-0.15
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	$0.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRX Adhera Therapeutics	-$2.11M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GLGLF GLG Life Tech	$48.29M	$1.32	0.00	N/A	N/A	498.04%	N/A	-76.15%	N/A
ORGS Orgenesis	-$55.36M	N/A	0.00	∞	N/A	-3,827.81%	N/A	-130.18%	11/11/2025 (Estimated)
WINT Windtree Therapeutics	-$1.79M	-$823.47	N/A	N/A	N/A	N/A	-207.34%	-50.19%	N/A

Latest ATRX, ORGS, WINT, and GLGLF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	WINT Windtree Therapeutics	-$99.00	-$3.06	+$95.94	-$3.06	$3.00 million	N/A
5/30/2025	Q1 2025	GLGLF GLG Life Tech	N/A	-$0.06	N/A	-$0.05	N/A	$2.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRX Adhera Therapeutics	N/A	N/A	N/A	N/A	N/A
GLGLF GLG Life Tech	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRX Adhera Therapeutics	N/A	N/A	N/A
GLGLF GLG Life Tech	N/A	0.21	0.19
ORGS Orgenesis	N/A	0.07	0.07
WINT Windtree Therapeutics	N/A	0.43	0.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRX Adhera Therapeutics	N/A
GLGLF GLG Life Tech	N/A
ORGS Orgenesis	22.56%
WINT Windtree Therapeutics	29.33%

Insider Ownership

Company	Insider Ownership
ATRX Adhera Therapeutics	28.20%
GLGLF GLG Life Tech	N/A
ORGS Orgenesis	5.66%
WINT Windtree Therapeutics	0.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRX Adhera Therapeutics	2	11.63 million	8.35 million	Not Optionable
GLGLF GLG Life Tech	12	38.39 million	N/A	Not Optionable
ORGS Orgenesis	150	4.80 million	4.53 million	No Data
WINT Windtree Therapeutics	30	3.66 million	3.66 million	Not Optionable

ATRX, ORGS, WINT, and GLGLF Headlines

Recent News About These Companies

Warrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ Delisting

2 hours ago | msn.com

BNB Treasury Firm Windtree Therapeutics Plunges 77% After Nasdaq Delisting Notice

August 22, 2025 | thecurrencyanalytics.comT

BNB treasury company plunges 77% after Nasdaq delisting notice

August 22, 2025 | cointelegraph.com

BNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delisting

August 20, 2025 | fxstreet.com

Nasdaq to Delist BNB Treasury Firm Windtree Therapeutics, Stock Crashes 76%

August 20, 2025 | coingape.comC

Windtree Therapeutics Faces Nasdaq Delisting Notice

August 20, 2025 | msn.com

Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

August 20, 2025 | americanbankingnews.com

Windtree Therapeutics Delays Q2 2025 Report Filing

August 14, 2025 | tipranks.com

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

August 11, 2025 | globenewswire.com

Windtree Therapeutics Terminates SEISMiC-C Clinical Study

August 11, 2025 | theglobeandmail.com

Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results

August 7, 2025 | msn.com

Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

August 5, 2025 | taiwannews.com.twT

Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout

July 30, 2025 | msn.com

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

July 29, 2025 | globenewswire.com

Windtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto Pivot

July 26, 2025 | thecurrencyanalytics.comT

Windtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time High

July 26, 2025 | techstory.inT

Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings

July 26, 2025 | msn.com

Windtree Therapeutics Targets $520 Million in Funding to Secure BNB Reserve

July 25, 2025 | beincrypto.comB

Nasdaq-listed Windtree Therapeutics Commits $520M to BNB in Bold Treasury Pivot

July 25, 2025 | blockonomi.com

Windtree Therapeutics Taps $520M to Build BNB Reserves — Is Pharma Going Crypto?

July 25, 2025 | crypto-news-flash.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRX, ORGS, WINT, and GLGLF Company Descriptions

Adhera Therapeutics OTCMKTS:ATRX

$0.01 0.00 (0.00%)

As of 08/26/2025

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

GLG Life Tech OTCMKTS:GLGLF

GLG Life Tech Corporation researches for, develops, grows, refines, and produces natural sweeteners extracted from the stevia plant and monk fruit in Canada and internationally. It also offers P-Pro Plus, a pea protein product; REB M GOLD, a bioconverted Rebaudioside M and Rebaudioside D. sweetener; and natural ingredients. It serves in the food and beverage industry. The company was formerly known as GLG Life Tech Limited and changed its name to GLG Life Tech Corporation in March 2007. GLG Life Tech Corporation was incorporated in 1998 and is headquartered in Richmond, Canada.

Orgenesis NASDAQ:ORGS

$1.00 +0.98 (+4,445.45%)

As of 12:04 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Windtree Therapeutics NASDAQ:WINT

$0.10 +0.00 (+1.55%)

As of 03:58 PM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time